Loading clinical trials...

Pilot Study: Mindfulness-Based Cognitive Therapy as a Tool for Prophylactic Mood Stabilizing Therapy in Bipolar Disorder | Clinical Trials | Clareo Health

COMPLETED

Pilot Study: Mindfulness-Based Cognitive Therapy as a Tool for Prophylactic Mood Stabilizing Therapy in Bipolar Disorder

NCT00999765•Douglas Mental Health University Institute

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the feasibility and short-term efficacy of MBCT as an add-on (i.e. patients must be stable with their regular mood stabilizing medication) for the maintenance therapy of bipolar disorder.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Males or females (\>18 years old)
•Bipolar disorder (as per the Structured Clinical Interview for DSM Disorders (SCID)(22)), euthymic state: Complete remission for at least four weeks ((Montgomery and Asberg Rating Scale (MADRS) ≤ 6 and item-1 (depressed mood) = 0 and no suicidal ideations (MADRS(item-10) \< 4)
•Must have had at least 3 depressive phases in the last 5 years
•Cooperative and willing to complete all the aspects of the study and especially the 45 minutes of exercise per day
•Must have completed a Secondary V (11th grade) education

Exclusion Criteria

•Other active psychiatric disorders (as per the SCID)
•Rapid cycling
•Bipolar disorder secondary to a medical condition or substance-induced mood disorder
•Suicidal ideations (MADRS(item 10)\>3)
•Active i.e. unstable and/or untreated medical condition
•Substance abuse (defined as per DSM-IV) in the last four weeks
•CBT (No more than four sessions (ever))
•Previous participation in a psychoeducation group within the last 6 months
•Current other psychotherapy (more than once a month)
•Practice of meditation (more than once a month) during the last two years
+3 more criteria

Locations (1)

Douglas Mental Health University Institute

Montreal, Quebec, Canada

Key Dates

Start Date

June 1, 2008

Primary Completion Date

March 1, 2010

Completion Date

December 1, 2012

Last Updated

May 15, 2023

Enrollment

ACTUAL participants

Conditions

Bipolar Disorder

Interventions

Mindfulness-Based Cognitive Therapy

BEHAVIORAL

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918

Treatment Resistant DepressionMajor Depressive Episode+5 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913

ManiaBipolar Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 15, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pilot Study: Mindfulness-Based Cognitive Therapy as a Tool for Prophylactic Mood Stabilizing Therapy in Bipolar Disorder

Inclusion Criteria

Exclusion Criteria

University of Iowa Interventional Psychiatry Service Patient Registry

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations

CBT-CP for Veterans With SMI

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Early Intervention for Youth at High Risk for Bipolar Disorder